On Jun. 1, 2020, Emergent BioSolutions announced it had been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.